GlaxoSmithKline PLC (GSK)

42.28
0.04 0.09
NYSE : Health Care
Prev Close 42.32
Open 42.26
Day Low/High 42.15 / 42.42
52 Wk Low/High 37.20 / 45.58
Volume 2.07M
Avg Volume 3.38M
Exchange NYSE
Shares Outstanding 2.44B
Market Cap 103.10B
EPS 0.50
P/E Ratio 24.32
Div & Yield 2.30 (5.40%)

Latest News

GlaxoSmithKline, Chubb, XPO Logistics, FedEx: 'Mad Money' Lightning Round

GlaxoSmithKline, Chubb, XPO Logistics, FedEx: 'Mad Money' Lightning Round

Jim Cramer is bullish on GlaxoSmithKline, Chubb, XPO Logistics and FedEx; he's bearish on ZTO Express and Advanced Semiconductor Engineering.

GSK's Board Faces Pressure Over Incoming CEO's Pay

GSK's Board Faces Pressure Over Incoming CEO's Pay

GlaxoSmithKline faces a rebellion from shareholders over the pay package of its incoming CEO Emma Walmsley, the U.K.'s top businesswoman

These Are the Signs of a Healthy Stock Market: Cramer's 'Mad Money' Recap (Thursday, 3/2/2107)

These Are the Signs of a Healthy Stock Market: Cramer's 'Mad Money' Recap (Thursday, 3/2/2107)

It wasn't an up day for the markets, but it's great news when a critical IPO goes off without any major problems, says Jim Cramer.

Is This The Best Biotech Play for 2017?

Is This The Best Biotech Play for 2017?

Is this small-cap biotech play the best way to profit from the growing worldwide demand for vaccines?

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Why I'm Optimistic About GlaxoSmithKline

Why I'm Optimistic About GlaxoSmithKline

Check out GSK's well developed base pattern.

Positive Results For Relvar® Ellipta® Lung Function Study In Patients With Well-Controlled Asthma

Positive Results For Relvar® Ellipta® Lung Function Study In Patients With Well-Controlled Asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from a non-inferiority lung function study, which demonstrated that patients with well-controlled...

Korn Ferry Futurestep Partners With GlaxoSmithKline To Support Talent Acquisition

Korn Ferry Futurestep Partners With GlaxoSmithKline To Support Talent Acquisition

Futurestep division of Korn Ferry (NYSE:KFY), the preeminent global people and organisational advisory firm, has been appointed by GlaxoSmithKline (NYSE:GSK), one of the world's largest science-led global healthcare...

Gilead Has 'Good News' But is it Enough?

Gilead Has 'Good News' But is it Enough?

Gilead Sciences' bictegravir suppressed HIV better than rival Glaxo's dolutegravir.

Gilead and 'Good News' Make A Rare, Joint Appearance at HIV Conference

Gilead and 'Good News' Make A Rare, Joint Appearance at HIV Conference

With sales of its hepatitis C drugs falling and an oncology pipeline that has largely disappointed, bictegravir is vitally important for Gilead to defend and grow its dominant HIV franchise.

3 Stocks Poised for Gains Under the Donald Trump Era

3 Stocks Poised for Gains Under the Donald Trump Era

With stocks at record highs, there are still buying opportunities, but investors should be selective.

Glaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns

Glaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns

GlaxoSmithKline beat analysts' expectations for fourth-quarter sales and earnings Wednesday but warned of a significant hit this year from anticipated generic competition to its Advair asthma treatment.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures are rising Wednesday while European and Asian shares trade higher despite a continued dip in oil prices.

Earnings Preview: GlaxoSmithKline Likely to See Currency Boost; Advair Sales in Focus

Earnings Preview: GlaxoSmithKline Likely to See Currency Boost; Advair Sales in Focus

GlaxoSmithKline reports fourth-quarter earnings Wednesday, with investors looking for guidance on the fate of its key Advair drug and the recent pace of organic growth for new products sales.

Brexit Already Having a Negative Impact, Business Leaders Say

Brexit Already Having a Negative Impact, Business Leaders Say

The U.K.'s top business leaders have painted a pessimistic view of Brexit, with more than half of respondents in a survey saying that it is already having a negative impact.

Week Ahead: Trump Takes the Wheel as Fourth-Quarter Earnings Power On

Week Ahead: Trump Takes the Wheel as Fourth-Quarter Earnings Power On

Wall Street should expect the unexpected in week three of Trump's America.

An Ominous Pattern Emerges

Don't get stranded on this island reversal.

Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks

Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks

Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.

GM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000

GM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000

Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Hey, What About the Transports?

They were red today and no one seems to care.

'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More

'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More

Jim Cramer favors UnitedHealth over Cerner, and U.S. Concrete more than Cemex.

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

Get used to some down days, says Jim Cramer, but don't lose sight of the success for financial stocks.

GSK Starts Phase III Study Of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI In Patients With Asthma

GSK Starts Phase III Study Of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI In Patients With Asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the start of a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone...

How You Can Profit as the Market for COPD Drugs Grows

How You Can Profit as the Market for COPD Drugs Grows

Hundreds of millions of people worldwide suffer from chronic respiratory disease. Here's how investors can profit from the companies making strides in treating COPD.

Pfizer Takes $106 Million Fine From U.K. for Price Hike of Epilepsy Drug

Pfizer Takes $106 Million Fine From U.K. for Price Hike of Epilepsy Drug

The U.K. regulator takes exception to the sale of Epanutin to Flynn Pharma, which drove the price up by 2,600%.

How to Buy GlaxoSmithKline at a 15% Discount

How to Buy GlaxoSmithKline at a 15% Discount

Investors seeking more returns can not only get some yield, but also healthy dividends from buying options on stocks. Those who are seeking additional opportunities can purchase GlaxoSmithKline (GSK),